Related Experiment Video
Updated: Jul 21, 2026
13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
High-content drug screening for rare diseases.
F Bellomo1,2, D L Medina3, E De Leo4
1Division of Nephrology and Dialysis, Bambino Gesù Children's Hospital - IRCCS, Piazza S. Onofrio, 4, 00165, Rome, Italy. francesco.bellomo@opbg.net.
Journal of Inherited Metabolic Disease
|June 9, 2017
Summary
High-throughput screening (HTS) and high-content screening (HCS) accelerate drug discovery for rare diseases by automating compound testing. These methods are crucial for drug repositioning and advancing personalized medicine.
Area of Science:
- Pharmacology and Drug Discovery
- Genetics and Genomics
- Computational Biology
Background:
- Rare diseases affect small populations but pose a significant treatment challenge.
- Therapy development for rare diseases faces hurdles like limited physiopathology knowledge, small patient cohorts, and low commercial interest.
Purpose of the Study:
- To highlight the role of high-throughput and high-content screening in rare disease therapy development.
- To explore the potential of these screening methods for drug repositioning and personalized medicine.
Main Methods:
- Utilized advances in robot- and computer-assisted technologies for automated compound screening.
- Employed experimental disease models for efficient testing of numerous compounds.
- Leveraged drug repositioning to identify existing drugs for rare disease treatment.
Main Results:
- High-throughput screening (HTS) and high-content screening (HCS) enable rapid screening of large compound libraries.
- Drug repositioning via HTS/HCS reduces the need for extensive preclinical testing by focusing on compounds already evaluated in humans.
Conclusions:
- Automated screening technologies are vital for overcoming obstacles in rare disease drug development.
- Future applications include computational modeling and artificial neural networks for predicting personalized clinical responses.
Related Concept Videos
02:46Genetic Screens
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:23Drug Concentrations: Measurements
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma —...
Plasma —...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...